Please be aware that Mahajan Imaging & Labs will never request for your bank details or OTP for booking/registration purposes.

What is a PDL1-IHC 22C3?

The PD-L1 IHC 22C3 test is an immunohistochemistry (IHC) assay performed on tumor tissue to detect the presence of PD-L1 (Programmed Death-Ligand 1) protein. PD-L1 expression is an important biomarker used to guide immunotherapy decisions, particularly in cancers such as lung carcinoma, head and neck cancers, and others. This test helps oncologists determine whether a patient may benefit from immune checkpoint inhibitors, making it a crucial step in personalized cancer treatment planning.

Additional Information

Also known as/ Other names: PD-L1 22C3 IHC Test, PD-L1 (22C3) Immunohistochemistry, PD-L1 22C3 PharmDx, PD-L1 Expression by IHC 22C3
Parameters: 1
Recommended for: M/F/Others
Sample Type: FFPE Tissue block
Patient Preparation: No prior preparation is needed
Reports: FFPE Block: 6 days Fresh Tissue: 10 days

FAQs

Why is this test important?

It helps identify patients who may benefit from immune checkpoint inhibitors, improving personalized cancer treatment outcomes.

Who should undergo this test?

Patients diagnosed with certain cancers, especially non-small cell lung cancer, may be recommended for PD-L1 testing.

What happens if PD-L1 is positive?

Positive PD-L1 expression suggests potential benefit from immunotherapy drugs like pembrolizumab.

What does a negative result mean?

It indicates low or absent PD-L1 expression, making immunotherapy less likely to be effective.

Can medications affect the test results?

No, medications do not interfere with PD-L1 protein detection in tissue samples.

How often should the test be repeated?

It is usually performed once per tumor diagnosis, though repeat testing may be needed if cancer recurs.

Can PD-L1 expression be prevented?

No, it is a biological characteristic of the tumor, not preventable.

Recommend more for you

Book Your Test
Text copied to clipboard
Dynamic badges will be added here